Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320032920> ?p ?o ?g. }
- W4320032920 endingPage "614" @default.
- W4320032920 startingPage "603" @default.
- W4320032920 abstract "Uterine serous carcinoma (USC) exhibits worse survival rates compared to the endometrioid subtype, and there is currently no effective treatment options for recurrence of this disease after platinum-based chemotherapy. Activation of PIK3CA/AKT/mTOR signaling pathway is a common biological feature in USC.Ipatasertib (IPAT) is an investigational, orally administered, ATP-competitive, highly selective inhibitor of pan AKT that has demonstrated anti-proliferative activity in a variety of tumor cells and tumor models. In this study, we used IPAT, carboplatin and their combination to investigate the anti-tumor activity in SPEC-2 and ARK-1 cells.Our results indicate that IPAT combined with carboplatin at low doses was more effective at reducing proliferation, inducing apoptosis and causing cellular stress than IPAT or carboplatin alone. In particular, inhibition of the PIK3CA/AKT/mTOR pathway and induction of DNA damage were involved in the synergistic inhibition by combination treatment of cell viability in USC cells treated with the combination. Furthermore, IPAT in combination with carboplatin significantly reduced cell adhesion and inhibited cell invasion.These findings suggest that the combination of IPAT and carboplatin has potential clinical implications for developing new USC treatment strategies." @default.
- W4320032920 created "2023-02-12" @default.
- W4320032920 creator A5007925500 @default.
- W4320032920 creator A5030381261 @default.
- W4320032920 creator A5044552904 @default.
- W4320032920 creator A5058573976 @default.
- W4320032920 creator A5062151371 @default.
- W4320032920 creator A5069234593 @default.
- W4320032920 creator A5074044247 @default.
- W4320032920 creator A5084844090 @default.
- W4320032920 date "2023-02-11" @default.
- W4320032920 modified "2023-10-15" @default.
- W4320032920 title "Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma" @default.
- W4320032920 cites W1578932543 @default.
- W4320032920 cites W1638147534 @default.
- W4320032920 cites W1984136423 @default.
- W4320032920 cites W2001208964 @default.
- W4320032920 cites W2003811411 @default.
- W4320032920 cites W2026135138 @default.
- W4320032920 cites W2044387885 @default.
- W4320032920 cites W2047331598 @default.
- W4320032920 cites W2060253107 @default.
- W4320032920 cites W2061365028 @default.
- W4320032920 cites W2064030312 @default.
- W4320032920 cites W2094875155 @default.
- W4320032920 cites W2098960933 @default.
- W4320032920 cites W2118510249 @default.
- W4320032920 cites W2118549314 @default.
- W4320032920 cites W2159750196 @default.
- W4320032920 cites W2162409477 @default.
- W4320032920 cites W2394642975 @default.
- W4320032920 cites W2394944900 @default.
- W4320032920 cites W2496572592 @default.
- W4320032920 cites W2550697711 @default.
- W4320032920 cites W2581413707 @default.
- W4320032920 cites W2741309469 @default.
- W4320032920 cites W2743639018 @default.
- W4320032920 cites W2747508608 @default.
- W4320032920 cites W2748521059 @default.
- W4320032920 cites W2802436949 @default.
- W4320032920 cites W2804985859 @default.
- W4320032920 cites W2886324201 @default.
- W4320032920 cites W2890266060 @default.
- W4320032920 cites W2891890640 @default.
- W4320032920 cites W2919235991 @default.
- W4320032920 cites W2945254664 @default.
- W4320032920 cites W2947372527 @default.
- W4320032920 cites W2949349304 @default.
- W4320032920 cites W2963015093 @default.
- W4320032920 cites W2975353236 @default.
- W4320032920 cites W2991107502 @default.
- W4320032920 cites W2999430041 @default.
- W4320032920 cites W3033644259 @default.
- W4320032920 cites W3045712044 @default.
- W4320032920 cites W3081108976 @default.
- W4320032920 cites W3119005666 @default.
- W4320032920 cites W3158705568 @default.
- W4320032920 cites W3159207021 @default.
- W4320032920 cites W3160537951 @default.
- W4320032920 cites W3178993660 @default.
- W4320032920 cites W3180644743 @default.
- W4320032920 cites W3191772847 @default.
- W4320032920 cites W3197880075 @default.
- W4320032920 cites W4206047804 @default.
- W4320032920 cites W4220794173 @default.
- W4320032920 cites W4226407945 @default.
- W4320032920 doi "https://doi.org/10.1080/07853890.2023.2177883" @default.
- W4320032920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36773034" @default.
- W4320032920 hasPublicationYear "2023" @default.
- W4320032920 type Work @default.
- W4320032920 citedByCount "0" @default.
- W4320032920 crossrefType "journal-article" @default.
- W4320032920 hasAuthorship W4320032920A5007925500 @default.
- W4320032920 hasAuthorship W4320032920A5030381261 @default.
- W4320032920 hasAuthorship W4320032920A5044552904 @default.
- W4320032920 hasAuthorship W4320032920A5058573976 @default.
- W4320032920 hasAuthorship W4320032920A5062151371 @default.
- W4320032920 hasAuthorship W4320032920A5069234593 @default.
- W4320032920 hasAuthorship W4320032920A5074044247 @default.
- W4320032920 hasAuthorship W4320032920A5084844090 @default.
- W4320032920 hasBestOaLocation W43200329201 @default.
- W4320032920 hasConcept C126322002 @default.
- W4320032920 hasConcept C190283241 @default.
- W4320032920 hasConcept C2776694085 @default.
- W4320032920 hasConcept C2776999253 @default.
- W4320032920 hasConcept C2778239845 @default.
- W4320032920 hasConcept C2781451048 @default.
- W4320032920 hasConcept C502942594 @default.
- W4320032920 hasConcept C55493867 @default.
- W4320032920 hasConcept C62112901 @default.
- W4320032920 hasConcept C71924100 @default.
- W4320032920 hasConcept C75217442 @default.
- W4320032920 hasConcept C86554907 @default.
- W4320032920 hasConcept C86803240 @default.
- W4320032920 hasConcept C98274493 @default.
- W4320032920 hasConceptScore W4320032920C126322002 @default.
- W4320032920 hasConceptScore W4320032920C190283241 @default.
- W4320032920 hasConceptScore W4320032920C2776694085 @default.